Pan Cancer T is at the forefront of immunotherapy, specifically focusing on next-generation TCR-T cell therapies designed to target solid tumors. Their approach leverages genetically modified T cells that are engineered to recognize and attack specific antigens present on tumor cells. This innovative therapy is built upon a unique set of 30 untapped targets that are exclusively expressed in various solid cancers, allowing for a more precise and effective treatment strategy. By enhancing the durability of these T cells, Pan Cancer T aims to achieve deeper and more sustained clinical responses, addressing significant challenges in the treatment of solid tumors.

The company is developing a comprehensive pipeline of TCR therapeutics aimed at ten major solid tumors, with their lead program, PCT-1, already showing promising safety and efficacy results in preclinical models, particularly for triple-negative breast cancer and melanoma. This program not only serves as a foundation for further research and clinical development but also highlights Pan Cancer T's commitment to providing effective treatment options for patients with difficult-to-treat tumors. Their expertise in discovery and T cell drug development positions them uniquely within the TCR space, as they continue to explore additional oncology indications, including bladder, ovarian, lung, esophagus, colon, prostate, and glioma cancers.

Netherlands

Pan Cancer T is a biotechnology spin-out (Erasmus MC, Rotterdam) focussed on the discovery and development of T cell receptor (TCR) T cell therapies. We exploit the 20 years of pioneering in adoptive T cell therapy as a springboard to breakthrough treatment of solid tumors.

Pan Cancer T develops natural affinity TCR T cell therapies towards unique and proprietary intracellular targets expressed by multiple solid tumors, and make T cell therapy maximally accessible despite the tumor micro-environment challenges.

Pan Cancer T

Company Details